Peptides and combination of peptides for use in immunotherapy against prostate cancer and other cancers

Patent metadata

Field	Value
Publication number	US-11826409-B2
Application number	US-202117320938-A
Country	US
Kind code	B2
Filing date	May 14, 2021
Priority date	Aug 5, 2015
Publication date	Nov 28, 2023
Grant date	Nov 28, 2023

Abstract

The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

First claim

The invention claimed is:

1. A peptide consisting of the amino acid sequence VTAQIGIVAV (SEQ ID NO: 1) in the form of a pharmaceutically acceptable salt.

2. The peptide of claim 1 , wherein said peptide has the ability to bind to an MHC class-I molecule, and wherein said peptide, when bound to said MHC, is capable of being recognized by CD8 T cells.

3. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is chloride salt.

4. The peptide of claim 1 , wherein the pharmaceutically acceptable salt is acetate salt.

5. A composition comprising the peptide of claim 1 , wherein the composition comprises an adjuvant and a pharmaceutically acceptable carrier.

6. The composition of claim 5 , wherein the peptide is in the form of a chloride salt.

7. The composition of claim 5 , wherein the peptide is in the form of an acetate salt.

8. The composition of claim 5 wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, poly-(I:C) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.

9. The composition of claim 8 , wherein the adjuvant is IL-2.

10. The composition of claim 8 , wherein the adjuvant is IL-7.

11. The composition of claim 8 , wherein the adjuvant is IL-12.

12. The composition of claim 8 , wherein the adjuvant is IL-15.

13. The composition of claim 8 , wherein the adjuvant is IL-21.

14. A pegylated peptide consisting of the amino acid sequence of VTAQIGIVAV (SEQ ID NO: 1) or a pharmaceutically acceptable salt thereof.

15. The peptide of claim 14 , wherein the pharmaceutically acceptable salt is chloride salt.

16. The peptide of claim 14 , wherein the pharmaceutically acceptable salt is acetate salt.

17. A composition comprising the pegylated peptide of claim 14 or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

18. A peptide consisting of the amino acid sequence of VTAQIGIVAV (SEQ ID NO: 1), wherein at least one amino acid of the peptide is a D-amino acid.

19. The peptide in the form of a pharmaceutically acceptable salt of claim 1 , wherein said peptide is produced by solid phase peptide synthesis or produced by a yeast cell or bacterial cell expression system.

20. A composition comprising the peptide of claim 1 , wherein the composition is a pharmaceutical composition and comprises water and a buffer.

Assignees

• Immatics Biotechnologies Gmbh

Inventors

• Mahr Andrea
• Weinschenk Toni
• Schoor Oliver
• Fritsche Jens
• Singh Harpreet
• Mueller Phillip
• Leibold Julia
• Goldfinger Valentina

Classifications

• G01N33/57557

  of other specific parts of the body, e.g. brain · CPC title

• G01N33/57575

  involving oncogenic proteins · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title

• A61K40/42

  Cancer antigens · CPC title

• A61K2039/5158

  Antigen-pulsed cells, e.g. T-cells · CPC title